ArticleProbiotics and antimicrobial proteins2026
Clostridium butyricum Promotes Bone Remodeling by Activating Inflammatory Genes in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Clostridium butyricum (CB), a commensal gut bacterium with established probiotic properties, has demonstrated therapeutic potential in diverse human and animal pathologies. Despite its recognized benefits, the precise mechanisms underlying its influence on bone metabolism remain poorly understood. This study investigates the effects of CB on bone metabolism in murine models and elucidates the involved molecular pathways. Intragastric administration of CB to juvenile female mice significantly elevated osteogenic and osteoclastogenic gene expression profiles, correlating with increased bone mineral content (BMC) and bone mineral density (BMD). GC-MS metabolomic profiling identified butyric acid and acetic acid as primary bacterial metabolites. Subsequent in vitro analyses revealed that sodium butyrate (SB), sodium acetate (SA), and their combination (SB + SA) potently upregulated osteogenic/osteoclastogenic markers in total bone marrow adherent cells (BMCs). Concordant results were observed in vivo, where dietary supplementation with these metabolites enhanced bone remodeling. Notably, flow cytometry demonstrated significant expansion of CD45
Indexed as
Identifiers
40720063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.